AGT and / or REN gene modified non-human animal
By introducing human AGT or REN gene sequences into non-human animals and constructing humanized animal models, the problem of inaccurate in vitro screening and animal testing results in traditional drug development is solved, achieving more efficient drug development and more accurate disease simulation.
Patent Information
- Application Number
- CN202510798883.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-14
- Filing Date
- 2025-06-13
- Publication Date
- 2025-09-09
AI Technical Summary
In traditional drug development, in vitro screening methods cannot simulate the body's environment, resulting in a high failure rate in drug development, large differences in in vivo test results between humans and animals, and uncertain clinical trial results.
Construct a non-human animal model with modified AGT and/or REN genes, introduce the nucleotide sequence of human AGT or REN into the endogenous gene locus of the non-human animal through gene editing technology, and establish a humanized animal model to simulate the human disease environment and drug response.
It improves drug development efficiency, reduces R&D costs, provides more accurate simulations of interactions between human disease states and target sites, and reduces differences in clinical trial results.